Wide Variation in Clinicians' Assessment of New York Heart Association/World Health Organization Functional Class in Patients With Pulmonary Arterial Hypertension

Taichman, Darren B.; Mcgoon, Michael D.; Harhay, Michael O.; Archer-Chicko, Chris; Sager, Jeffrey S.; Murugappan, Meena; Chakinali, Murali M.; Palevsky, Harold I.; Gallop, Robert
July 2009
Mayo Clinic Proceedings;Jul2009, Vol. 84 Issue 7, p586
Academic Journal
OBJECTIVE: To assess interrater reliability of the New York Heart Association/World Health Organization functional classification as applied by clinicians (defined as both physicians and nurses in this article) to patients with pulmonary arterial hypertension (PAH). PATIENTS AND METHODS: Between March 16 and August 31, 2007, a survey that described 10 hypothetical patients was completed by physicians and nurses attending a conference on PAH. Results were subsequently validated with physicians and nurses who were contacted online through the Pulmonary Hypertension Association. Respondents were asked to assign each patient's functional class as they would normally in clinical practice. RESULTS: The functional class evaluations were completed by 113 clinicians, 87 (77%) of whom had participated in PAH trials; 106 (94%) reported using functional class when determining therapy. Clinicians reported a broad range of factors they considered when evaluating functional class, and their assessments of functional class varied widely. The intraclass correlation coefficient was 0.58 for the Initial patient survey and 0.62 for the online survey. At best, one patient was ranked as either class II (by 60 clinicians [53%]) or class III (by 53 [47%]). Clinicians' rankings spanned at least 3 functional classes for each of the other patients. Equally divergent rankings were observed among nurses and physicians. Cluster analysis identified clinicians' tendencies toward "higher" or "lower" functional class rankings. Of the 113 clinicians, 101 (89%) thought that the patients described resembled those seen in their practices. CONCLUSION: Despite the wide use of the New York Heart Association/World Health Organization functional class in clinical care and as a research tool, Interrater agreement may be inadequate. Efforts to promote a uniform approach to evaluating functional class might help to standardize PAH care and research.


Related Articles

  • Pharmacotherapy for pulmonary arterial hypertension. Changhwan Kim; Yong Bum Park // Journal of the Korean Medical Association / Taehan Uisa Hyophoe ;Dec2011, Vol. 54 Issue 12, p1299 

    Although pulmonary arterial hypertension (PAH) is an orphan disease with high mortality and for which there is no cure, current treatment have led to considerable gains in the outcomes of these patients. Oral anticoagulation is proposed for most patients; diuretic treatment and supplemental...

  • Latest Therapeutic Novelties and Patents in Pulmonary Hypertension. Hardavella, Georgia F.; Dionellis, Georgios S.; Kantza, Christina G.; Koulouris, Nikolaos G.; Alchanatis, Manos // Recent Patents on Cardiovascular Drug Discovery;Jan2011, Vol. 6 Issue 1, p55 

    Recent advances in technology and novel pharmaceutical research findings have added new grounds in the fields of medical treatment and quality of life of patients diagnosed with pulmonary arterial hypertension (PAH). Collective assessment of new data is mandatory and useful for specialist...

  • Spectrum of cardiac disease in maternity in a low-resource cohort in South Africa. Sliwa, Karen; Libhaber, Elena; Elliott, Catherine; Momberg, Zoe; Osman, Ayesha; Z├╝hlke, Liesl; Lachmann, Tony; Nicholson, Lauren; Thienemann, Friedrich; Roos-Hesselink, Jolien; Anthony, John // Heart;Dec2014, Vol. 100 Issue 24, p1967 

    Background Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of this study were to...

  • Cost-Utility of Treatments for Pulmonary Arterial Hypertension. Garin, Margaret C.; Clark, Leslie; Chumney, Elinor C. G.; Simpson, Kit N.; Highland, Kristin B. // Clinical Drug Investigation;2009, Vol. 29 Issue 10, p635 

    Background and Objective: Clinicians must choose between an increasing number of medications for the treatment of pulmonary arterial hypertension (PAH) with different routes of administration, adverse effects, costs and efficacies. We constructed a decision analysis to help inform treatment...

  • A rare cardiac cause of hoarseness of voice. Berekat, Ismail I.; Azzu, Abdulrahman // Libyan Journal of Medicine;Mar2010, Vol. 5 Issue 5, p1 

    The article focuses on Ortner's or cardio-vocal syndrome, the hoarseness of voice caused by the damage of the recurrent laryngeal nerve. Cardiac causes that could lead to such syndrome are cited including pulmonary hypertension, aneurysm of the pulmonary artery and Ductus arteriosus. The article...

  • New drug considered better way to treat pulmonary hypertension.  // Drug Topics;1/7/2002, Vol. 146 Issue 1, p20 

    Reports on the approval of an oral pill developed by Actelion USA for the treatment of pulmonary arterial hypertension in January 2002. Information on the disease; Mechanism of action of the drug. INSET: TIPS TO REMEMBER.

  • Chronic Thrombotic Obstruction of Major Pulmonary Arteries. Moser, Kenneth M.; Spragg, Roger G.; Utley, Joseph; Daily, Pat O. // Annals of Internal Medicine;Sep83, Vol. 99 Issue 3, p299 

    Examines patients with pulmonary hypertension associated with chronic thrombotic obstruction of major pulmonary arteries. Clinical features of patients with pulmonary hypertension; Diagnosis of the disease; Results of thromboendarterectomy.

  • Primary Pulmonary Hypertension Treated with Oral Phentolamine. Ruskin, Jeremy N.; Hutter Jr., Adolph M. // Annals of Internal Medicine;May79, Vol. 90 Issue 5, p772 

    Presents information on a study which evaluated the treatment trial of a patient with symptomatic primary pulmonary artery hypertension with parenteral and oral phentolamine. Information on primary pulmonary artery hypertension; Medical history of the patient; Results and discussion.

  • New insights into the treatment of pulmonary arterial hypertension. Clavecilla, Stella Q. // Formulary;Mar2003, Vol. 38 Issue 3, p150 

    Provides alternative insights into the treatment of pulmonary arterial hypertension. Etiology and pathophysiology; Diagnostic procedures; Disease management; Therapeutic considerations.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics